TIDMINHC
RNS Number : 5230I
Induction Healthcare Group PLC
05 December 2022
Induction Healthcare Group PLC
("Induction", the "Company", or the "Group")
Directorate Changes
Appointment of Senior Independent Director
Appointment of Interim Chief Financial Officer
Induction (AIM: INHC), a leading digital health platform driving
transformation of healthcare systems worldwide, announces the
following Board changes. Ian Johnson has been appointed to the
Board as the Senior Independent Director ('SID') replacing
Leslie-Ann Reed who will be stepping down following completion of
her three-year
term. Andy Williams is also appointed Chair of the Audit Committee.
Alongside this, Guy Mitchell, will step down from his position
as Chief Financial Officer ('CFO') due to personal reasons and will
be replaced by John McIntosh as interim CFO, a non-Board position.
Guy has resigned as a Director with immediate effect, but will
remain with the business for a short handover period.
Ian Johnson appointed as Senior Independent Director
Ian brings over 30 years of Board experience working with quoted
and private companies in the Life Sciences space, having spent a
career providing strategic direction and business development
expertise. He has a proven track record of overseeing business
growth and providing commercial advice through scale-up, organic
growth and M&A activity.
Ian is currently Executive Chairman of NIOX Group plc, a
business focused on improving asthma diagnosis and management. In
addition, Ian is Operational Adviser at Harwood Private Equity
focusing on the Life Sciences sector. He was founder and CEO of
Biotrace International Plc before its sale to 3M in December 2006
and has previously been SID of Clinigen plc. Ian has also acted as
Executive Chairman for Bioquell PLC, Non-Executive Chairman of
Quantum Pharma plc, Cyprotex PLC, Biofortuna Limited and Celsis
Group and Non-Executive Director of Ergomed PLC.
John McIntosh appointed as Interim CFO
John is a highly experienced AIM CFO who has worked as a
consultant CFO, interim Finance Director and CFO for public and
private entities in the UK, USA, and Europe. After qualifying with
Deloitte in 1994, John worked with SONY, DMB&B and the BBC,
before focusing towards online, and multi-media businesses.
John was Director and CFO of Bidstack Group plc ("Bidstack") for
three years until 2021, where he led the business from its early
stages, through its successful admission to AIM in September 2018,
to become a leading multi-market international business . Prior to
this, he was interim FD and Board member of Progility PLC for three
years. He was also CFO and Chief Operating Officer for DCD Media
plc for five years.
John's appointment is an interim role, and the Board are
actively recruiting to appoint a permanent CFO.
Induction CEO, James Balmain, said: "I would like to extend my
thanks of behalf of the Board to Leslie-Ann for her contribution
during a transformation period. We are grateful for Leslie-Ann's
support, and she will be missed.
"I wish Guy the very best for the future and would like to
welcome John and Ian, who both bring extensive AIM experience to
Induction."
Disclosures in accordance with the AIM Rules
Mr Ian Roy Johnson, aged 69, is, or has been, a director or
partner of the following companies or partnerships during the past
five years:
Current directorships and/or Former directorships and/or partnerships
partnerships (within the last five years)
NIOX Group plc Ergomed PLC
Circassia Limited Redcentric PLC
Clinigen PLC
Bioquell PLC
Bioquell UK Limited
Bioxyquell Limited
MDH Defence Limited
Klenitise Limited
Prosonix Limited
Circassia Pharma Limited
Mr Johnson owns 20,000 shares in Induction.
Mr Johnson was appointed director of Pure Options Solutions
Limited in December 2009. Pure Options Solutions Limited
subsequently entered into administration in November 2010 and the
company was dissolved following liquidation in September 2014. The
estimated deficiency to investors and creditors was approximately
GBP4.5 million.
Mr Johnson was appointed director of Toximet Limited in
September 2013. Toximet Limited subsequently entered into
administration in November 2015, creditors voluntary liquidation in
November 2016 and was dissolved following liquidation in August
2017. The estimated deficiency to investors and creditors was
approximately GBP0.8 million.
There are no further disclosures required in accordance with AIM
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies.
ENQUIRIES
Induction Via Walbrook PR Ltd: induction@walbrookpr.com
James Balmain, Chief Executive Officer
Christopher Samler, Non-Executive
Chair
Singer Capital Markets (Nominated
Adviser and Broker) +44 (0)20 7496 3000
Philip Davies / Kailey Aliyar
Walbrook PR Ltd induction@walbrookpr.com
Alice Woodings / Paul McManus Mob: +44 (0)7407 804 654 / +44(0)7980
541 893
About Induction - www.inductionhealthcare.com
Induction (AIM: INHC) Induction delivers a suite of software
solutions through a single integrated platform that transforms care
delivery. Our system-wide applications help healthcare providers
and administrators to deliver care at any stage remotely as well as
face-to-face - giving the communities they serve greater
flexibility, control and ease of access. Purpose-built for
integration with leading Electronic Medical Record (EMR) platforms,
our products offer immediate stand-alone value that becomes even
greater when integrated with pre-existing systems.
Used at scale by national and regional healthcare systems, as
well non-health government services, our applications are relied
upon by hundreds of thousands of clinicians and millions of
patients across almost every hospital in the British Isles.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAAALEAPAFAA
(END) Dow Jones Newswires
December 05, 2022 02:01 ET (07:01 GMT)
Induction Healthcare (LSE:INHC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Induction Healthcare (LSE:INHC)
Historical Stock Chart
From Jul 2023 to Jul 2024